Matches in SemOpenAlex for { <https://semopenalex.org/work/W2590773620> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W2590773620 endingPage "7580" @default.
- W2590773620 startingPage "7580" @default.
- W2590773620 abstract "7580 Background: In the present analysis we evaluated the clinical outcome of KRAS mutated advanced non-small cell lung cancer (NSCLC) patients (pts) treated at a single Institution from April 2007 to December 2010. Methods: KRAS mutational status was assessed on tumor tissue collected at the time of first diagnosis (either primary or metastatic). KRAS (exons 2 and 3) gene was amplified by nested PCR and sequenced in both sense and antisense direction using 3500 Genetic Analyzer. Retrospective chart review was approved by the local Ethics Committee. Results: 64 pts with an identified KRAS mutation were evaluable for the analysis. The majority of them (87.5%) had a good performance status (ECOG 0), while 82.5% were former or current smokers. All pts except for one who was treated with single-agent gemcitabine, received a platinum-based doublet mainly including either gemcitabine (56,5%) or pemetrexed (25%). Overall, 82% of pts received at least two lines of chemotherapy. Three types of KRAS mutations were identified, the most common being codon 12 (78.1%) mutation, followed by codon 13 (12.5%) and codon 61 (9.4%) mutations, respectively. Of the 52 (81,2%) who were evaluable for response 2 complete responses (3,8%), 21 partial responses (40,4%), 13 disease stabilizations (25%) and 16 progressive diseases (30,8%) were observed. Median overall survival (OS) from the beginning of treatment was 39 months, with no statistically significant differences according to the type of K-RAS mutation (p< 0,2). Median OS and first-line PFS were significantly higher in responders versus non-responders (55.4 months versus 24.8 months for OS and 11.2 months versus 4.8 months for first-line PFS, p<0.009). Conclusions: KRAS mutated NSCLC pts do not represent a population with homogeneous clinical characteristics. Response to treatment seems to predict benefit from first-line chemotherapy in terms of OS and first-line PFS. The excellent OS rate observed in the whole group might be the result of a population highly selected for good clinical prognostic factors. Prospective studies of KRAS mutations and sensitivity to chemotherapy are warranted." @default.
- W2590773620 created "2017-03-03" @default.
- W2590773620 creator A5008403882 @default.
- W2590773620 creator A5015720107 @default.
- W2590773620 creator A5017646398 @default.
- W2590773620 creator A5021264126 @default.
- W2590773620 creator A5034761732 @default.
- W2590773620 creator A5050990221 @default.
- W2590773620 creator A5052032389 @default.
- W2590773620 creator A5062180939 @default.
- W2590773620 creator A5078588212 @default.
- W2590773620 creator A5079039762 @default.
- W2590773620 date "2011-05-20" @default.
- W2590773620 modified "2023-10-16" @default.
- W2590773620 title "Clinical outcome of KRAS-mutated advanced non-small cell lung cancer (NSCLC) patients (pts): A mono-institutional analysis." @default.
- W2590773620 doi "https://doi.org/10.1200/jco.2011.29.15_suppl.7580" @default.
- W2590773620 hasPublicationYear "2011" @default.
- W2590773620 type Work @default.
- W2590773620 sameAs 2590773620 @default.
- W2590773620 citedByCount "0" @default.
- W2590773620 crossrefType "journal-article" @default.
- W2590773620 hasAuthorship W2590773620A5008403882 @default.
- W2590773620 hasAuthorship W2590773620A5015720107 @default.
- W2590773620 hasAuthorship W2590773620A5017646398 @default.
- W2590773620 hasAuthorship W2590773620A5021264126 @default.
- W2590773620 hasAuthorship W2590773620A5034761732 @default.
- W2590773620 hasAuthorship W2590773620A5050990221 @default.
- W2590773620 hasAuthorship W2590773620A5052032389 @default.
- W2590773620 hasAuthorship W2590773620A5062180939 @default.
- W2590773620 hasAuthorship W2590773620A5078588212 @default.
- W2590773620 hasAuthorship W2590773620A5079039762 @default.
- W2590773620 hasConcept C121608353 @default.
- W2590773620 hasConcept C126322002 @default.
- W2590773620 hasConcept C143998085 @default.
- W2590773620 hasConcept C2776256026 @default.
- W2590773620 hasConcept C2776694085 @default.
- W2590773620 hasConcept C2777240266 @default.
- W2590773620 hasConcept C2778239845 @default.
- W2590773620 hasConcept C2778822529 @default.
- W2590773620 hasConcept C2780258809 @default.
- W2590773620 hasConcept C2781187634 @default.
- W2590773620 hasConcept C526805850 @default.
- W2590773620 hasConcept C71924100 @default.
- W2590773620 hasConcept C90924648 @default.
- W2590773620 hasConceptScore W2590773620C121608353 @default.
- W2590773620 hasConceptScore W2590773620C126322002 @default.
- W2590773620 hasConceptScore W2590773620C143998085 @default.
- W2590773620 hasConceptScore W2590773620C2776256026 @default.
- W2590773620 hasConceptScore W2590773620C2776694085 @default.
- W2590773620 hasConceptScore W2590773620C2777240266 @default.
- W2590773620 hasConceptScore W2590773620C2778239845 @default.
- W2590773620 hasConceptScore W2590773620C2778822529 @default.
- W2590773620 hasConceptScore W2590773620C2780258809 @default.
- W2590773620 hasConceptScore W2590773620C2781187634 @default.
- W2590773620 hasConceptScore W2590773620C526805850 @default.
- W2590773620 hasConceptScore W2590773620C71924100 @default.
- W2590773620 hasConceptScore W2590773620C90924648 @default.
- W2590773620 hasIssue "15_suppl" @default.
- W2590773620 hasLocation W25907736201 @default.
- W2590773620 hasOpenAccess W2590773620 @default.
- W2590773620 hasPrimaryLocation W25907736201 @default.
- W2590773620 hasRelatedWork W2020996031 @default.
- W2590773620 hasRelatedWork W2044560382 @default.
- W2590773620 hasRelatedWork W2086210085 @default.
- W2590773620 hasRelatedWork W2091102743 @default.
- W2590773620 hasRelatedWork W2181288074 @default.
- W2590773620 hasRelatedWork W2569260518 @default.
- W2590773620 hasRelatedWork W3011176692 @default.
- W2590773620 hasRelatedWork W3180757786 @default.
- W2590773620 hasRelatedWork W4254666574 @default.
- W2590773620 hasRelatedWork W2492085373 @default.
- W2590773620 hasVolume "29" @default.
- W2590773620 isParatext "false" @default.
- W2590773620 isRetracted "false" @default.
- W2590773620 magId "2590773620" @default.
- W2590773620 workType "article" @default.